Previous 10 | Next 10 |
PHILADELPHIA and OXFORDSHIRE, United Kingdom, Jan. 13, 2020 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, today announced the appointment of Dr. Elliot Norry as Senior Vice President and Chief Medical Officer (CMO) effective i...
Adaptimmune Therapeutics (NASDAQ: ADAP ) is up 60% premarket after reporting two confirmed Partial Responses (PRs) – one in a patient with liver cancer and one in a patient with melanoma. More news on: Adaptimmune Therapeutics plc, Healthcare stocks news, Stocks o...
- Partial Responses seen in liver, melanoma, gastro-esophageal junction, and head and neck cancers - - Encouraging demonstration of the potential of SPEAR T-cell platform across multiple targets and a range of solid tumors - PHILADELPHIA and OXFORDSHIRE, United Kingdom, Jan. 13, 2...
Company Overview Adaptimmune ( ADAP ) is a clinical-stage biotechnology company developing novel cell therapies in solid tumors. With their proprietary Specific Peptide Enhanced Affinity Receptor ("SPEAR") T cell platform, they identify cancer targets, find and genetically engineer T cell ...
PHILADELPHIA and OXFORDSHIRE, United Kingdom, Dec. 03, 2019 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that it has received Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. Food and ...
Introduction Cancer is the second leading cause of death globally, with an estimated 17.0 million new cases and 9.5 million deaths in 2018. By 2040, the global burden is expected to grow to 27.5 million new cases and 16.3 million deaths. Although most money in clinical development has ...
- Clinical responses in seven out of 14 patients with synovial sarcoma by RECIST 1.1 - - Clinical benefit in 13 out of 14 patients - - One RECIST response maintained for more than 9 months after SPEAR T-cell infusion - PHILADELPHIA and OXFORDSHIRE, United Kingdom, Nov. 16, 2019 ...
Adaptimmune Therapeutics PLC (ADAP) Q4 2019 Earnings Conference Call November 06, 2019, 08:00 ET Company Participants Juli Miller - Director, IR Adrian Rawcliffe - CEO, Principal Accounting Officer & Director Elliot Norry - Acting Chief Medical Officer John Lunger - Chief P...
Adaptimmune (NASDAQ: ADAP ): Q3 GAAP EPS of -$0.06 beats by $0.30 . More news on: Adaptimmune Therapeutics plc, Earnings news and commentary, Stocks on the move, Healthcare stocks news, , Read more ...
- Clinical responses with ADP-A2M4 in 7 out of 12 patients with synovial sarcoma, and clinical benefit in 11 out of 12 patients - - ADP-A2M4 granted Orphan Drug Designation for treatment of soft tissue sarcomas - - Enrolling across SPEARHEAD-1 and SURPASS trials at multiple sites ...
News, Short Squeeze, Breakout and More Instantly...
Adaptimmune Therapeutics plc Company Name:
ADAP Stock Symbol:
NASDAQ Market:
Adaptimmune Therapeutics plc Website:
Approved for advanced MAGE-A4+synovial sarcoma in adults with certain HLA types who have received prior chemotherapy TECELRA is the first new treatment option for people with synovial sarcoma in more than a decade Adaptimmune to hold webcast at https://www.gowebcasti...
2024-07-30 07:30:03 ET H.C. Wainwright analyst issues BUY recommendation for ADAP on July 30, 2024 06:07AM ET. ADAP was trading at $1.37 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 4 - Buy, 1 - Hold, ...
2024-07-30 07:00:10 ET Arthur He from H.C. Wainwright issued a price target of $4.00 for ADAP on 2024-07-30 06:07:00. The adjusted price target was set to $4.00. At the time of the announcement, ADAP was trading at $1.37. The overall price target consensus is at $2.54 wi...